Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Glaxo’s Revolade Wins U.K. Cost Agency’s Backing

Don't Miss Out —
Follow us on:

Dec. 18 (Bloomberg) -- GlaxoSmithKline’s Revolade wins backing of health-cost agency in draft guidance on treatment of a rare bleeding disorder after drugmaker agrees to sell it to state-run medical system at a discount. * Revolade is cost-effective for chronic immune

thrombocytopenic purpura in certain adults who have had

their spleens removed and those who haven’t responded to at

least one other therapy, National Institute for Health and

Clinical Excellence says in e-mailed statement * Decision reverses 2010 ruling that drug was too costly;

agency didn’t disclose size of discount Glaxo is offering


For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>